Reaction
Rubber Sensitivity reporting signals
As of the last recalculation, Rubber Sensitivity appears in 1,512 FAERS reports alongside 28 co-occurring drug terms. The strongest observed disproportionality signal is OMALIZUMAB (PRR 25.0).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Omalizumab | 141 | 25.0 | 25.1 |
| Candesartan Cilexetil | 45 | 24.2 | 24.3 |
| Erenumab-Aooe | 64 | 16.7 | 16.7 |
| Evolocumab | 156 | 14.7 | 14.7 |
| Calcium, Magnesium, Potassium, And Sodium Oxybates | 9 | 14.5 | 14.5 |
| Phytonadione | 8 | 13.0 | 13.1 |
| Tobramycin Solution | 10 | 11.5 | 11.5 |
| Valproate Sodium | 17 | 11.4 | 11.4 |
| Tobramycin Sulfate | 10 | 11.2 | 11.2 |
| Primidone | 8 | 10.9 | 10.9 |
| Adrenalinum | 32 | 10.8 | 10.8 |
| Febuxostat | 13 | 10.8 | 10.8 |
| Epinephrine | 44 | 9.5 | 9.5 |
| Dornase Alfa | 12 | 8.5 | 8.5 |
| Diclofenac Potassium, Film Coated | 5 | 8.2 | 8.2 |
| Diclofenac Potassium Tablets | 5 | 8.2 | 8.2 |
| Diclofenac Potassium | 6 | 7.7 | 7.7 |
| Tobramycin | 13 | 7.5 | 7.5 |
| Etanercept | 274 | 7.5 | 7.5 |
| Tiotropium Bromide | 66 | 6.9 | 6.9 |
| Asfotase Alfa | 5 | 6.9 | 6.9 |
| Secukinumab | 70 | 6.2 | 6.2 |
| Certolizumab Pegol | 41 | 4.9 | 4.9 |
| Sodium Oxybate | 22 | 4.6 | 4.6 |
| Avapritinib | 4 | 4.6 | 4.6 |
| Rimegepant Sulfate | 4 | 4.4 | 4.4 |
| Benralizumab | 6 | 4.1 | 4.1 |
| Ravulizumab | 4 | 4.1 | 4.1 |